25
Participants
Start Date
May 23, 2013
Primary Completion Date
May 10, 2018
Study Completion Date
May 10, 2018
Rituximab
Participants will receive rituximab 375 mg/m\^2 IV infusion on Days 1, 8, 15 and 22. Rituximab infusions will be given at a rate of 25 milligrams per hour (mg/h). This may be escalated at a rate of 25 mg/h increments every 30 minutes to a maximum of 200 mg/h.
COLUMBIA PRESBYTERIAN MEDICAL CENTER, Research Pharmacy, William Black Medical Research Building, New York
Childrens University Hospital, Belgrade
Istituto Giannina Gaslini-Ospedale Pediatrico IRCCS, Genoa
Clinical Center Nis, Niš
Universitätsklinikum für Kinder und Jugendmedizin Hamburg, Hamburg
Istanbul University, Cerrahpasa Medical Faculty; Pediatrics Department, Istanbul
Univ. Di Padova - Dip. Di Pediatria - Unita' Reumatol. Pediatrica, Padua
University of Louisville Research Foundation, Inc; Kosair Charities Pediatric Clinical Research Unit, Louisville
The Cleveland Clinic Foundation; Rheumatic and Immunologic Diseases, Cleveland
Cincinnati Childrens Hospital, Cincinnati
KfH-Nierenzentrum fur Kinder und Jugendliche, Heidelberg
Hopital Femme Mere Enfant; Ped Nephrologie Rhumatologie, Bron
Hop Necker Enfants Malades;UIH, Paris
University of Utah; Immunology/Rheumatology/Allergy, Salt Lake City
Hackensack University Medical Center, Hackensack
Alberta Children'S Hospital, Calgary
Children's and Women's Health Center / BC Children's Hospital, Vancouver
The Hospital for Sick Children Research Institute, Toronto
Irccs Ospedale Pediatrico Bambin Gesu - Dip. Di Medicina, Rome
Hacettepe University, School of Medicine; Pediatrics Department, Ankara
Alder Hey Children s Hospital; Department of Pediatrics, Liverpool
Great Ormond Street Children's Hospital; Centre of Paediatric & Adolescent Rheumatology, London
Nottingham Children's Hospital, Nottingham
Hoffmann-La Roche
INDUSTRY